Arcus Biosciences Inc. (RCUS)
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
📉 **NEGATIVE** • Medium confidence analysis (73%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (5%) **Content type:** Clinical